RCUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Dec. 2023, Arcus Biosciences received $3.0 Mil more from issuing new shares than it paid to buy back shares. It received $0.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, Arcus Biosciences earned $3.0 Mil on financial activities for the three months ended in Dec. 2023.
The historical data trend for Arcus Biosciences's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 1.12 | 439.00 | 237.00 | 33.00 | 33.00 |
Arcus Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 11.00 | 1.00 | 23.00 | 6.00 | 3.00 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Arcus Biosciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 33 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 |
= | 33.0 |
Arcus Biosciences's Cash from Financing for the quarter that ended in Dec. 2023 is:
Cash Flow from Financing | (Q: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 3 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 |
= | 3.0 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences (NYSE:RCUS) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Arcus Biosciences's issuance of stock for the three months ended in Dec. 2023 was $3.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Arcus Biosciences's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Arcus Biosciences's net issuance of debt for the three months ended in Dec. 2023 was $0.0 Mil. Arcus Biosciences received $0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Arcus Biosciences's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. Arcus Biosciences paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Arcus Biosciences's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. Arcus Biosciences received $0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Arcus Biosciences's other financing for the three months ended in Dec. 2023 was $0.0 Mil. Arcus Biosciences received $0.0 Mil on other financial activities.
Thank you for viewing the detailed overview of Arcus Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Goeltz Ii Robert C. | officer: Chief Financial Officer | 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080 |
Juan C. Jaen | director, 10 percent owner, officer: President | 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Jennifer Jarrett | officer: See Remarks | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Alexander Azoy | officer: Chief Accounting Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Terry J Rosen | director, 10 percent owner, officer: Chief Executive Officer | C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080 |
Carolyn C. Tang | officer: General Counsel | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
Dimitry Sa Nuyten | officer: Chief Medical Officer | 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710 |
Linda Slanec Higgins | director | 3610 LOUIS RD., PALO ALTO CA 94303 |
Nicole Lambert | director | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
William Grossman | officer: Chief Medical Officer | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Yasunori Kaneko | director, 10 percent owner | 509 ROEHAMPTON, HILLS BOROUGH CA 94010 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Michael Quigley | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew J Perlman | director | 618 MIRADA AVE, STANFORD CA 94305 |
From GuruFocus
By Business Wire • 10-24-2023
By Business Wire Business Wire • 03-02-2023
By Business Wire Business Wire • 05-17-2023
By Business Wire • 01-16-2024
By Business Wire • 08-09-2023
By Business Wire • 11-13-2023
By Business Wire Business Wire • 05-24-2023
By Business Wire • 07-25-2023
By Business Wire • 10-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.